logo
‘Science of reading' curriculum will soon be offered to all Tri-City K-5 students

‘Science of reading' curriculum will soon be offered to all Tri-City K-5 students

Yahoo30-03-2025
A new 'science of reading' core literacy curriculum piloted in Kennewick elementary schools is likely to set a better foundation for students to read, write and learn.
The Kennewick School Board on Wednesday unanimously approved the adoption of Amplify Core Knowledge Language Arts (CKLA) at the recommendation of district staff and a materials committee.
In September, with the start of the 2025-26 school year, all K-5 classes will use Amplify CKLA.
This comes after the district piloted it in 25 classrooms across seven elementary schools. STAR test scores between fall and winter showed 18 classes had the equivalent academic growth of more than a year.
It's the same curriculum adopted last year by the Richland School District. Pasco School District in 2022-23 adopted the American Reading Company's Core, which is 'informed' by science of reading research.
That means all 18,000 elementary students in the Tri-Cities region will soon be learning through a science of reading curriculum.
Science of reading is a broad term that refers to a comprehensive body of empirical research spanning several decades detailing what matters and what works in the field of holistic literacy instruction.
It narrows in on two component skills: decoding and linguistic comprehension. And it highlights five 'pillars' of reading proficiency that students need: phonemic awareness, phonics, fluency, vocabulary and comprehension.
Its approach in the classroom is known as 'structured literacy.' It's different from the 'balanced literacy' method that's been popular in classrooms for decades, which promotes a 'well-rounded and comprehensive education in reading and writing.'
Teachers in recent years have also moved away from 'three-cueing' in favor of more scientifically sound and specific strategies to help students with reading roadblocks.
That strategy, also known as MSV (meaning, syntax, visual), entails students drawing from context clues, visuals or sentence structure to guess at a word's meaning.
Jilian Alfaro, a 4th grade teacher at Sage Crest Elementary, says it enhanced her students' curiosity and comprehension of complex concepts.
'Every child has the right to a rigorous and meaningful learning experience in which they can naturally grow, inquire, discover their passions and succeed,' she told parents at a community preview event.
Early childhood literacy education is important because students begin to use reading and writing as a primary medium to learn other concepts by the time they're in the third-grade. It can be a crucial indicator of a student's future success in high school, college and the workforce.
Kennewick will purchase eight years of digital access and five years of print from Amplify, totaling $2 million — a good price for K-5 reading curriculum.
Since 2016 it's used Houghton Mifflin Harcourt's Journeys, but district staff moved up curriculum adoption earlier because the publisher is sunsetting the curriculum.
Alyssa St. Hilaire, Kennewick's assistant superintendent of teaching and learning, says the standout is that kids are 'excited and curious' to learn with Amplify CKLA.
'We also feel it's one of the best materials out there that's grounded in science of reading, and just really helping teach those skills in a systematic approach,' she said.
'Just hearing the kids be excited about learning about history and science is kind of the Velcro that helps all of that reading stick,' St. Hilaire said.
Students learn through shorter excerpts of learning with Journeys, while Amplify uses units to draw 'deeper learning' of concepts.
For example, science class might have a through line that goes from animals and habitats to eventually studying the plant cycle.
Past curricula taught skills in isolation, St. Hilaire says. But CKLA allows students to develop skills holistically through subject background knowledge.
Scarborough's Reading Rope shows what's going on in student brains as they build reading comprehension, St. Hilaire said.
Two 'strands' — language comprehension and word recognition — are foundational for students to build skilled reading. But those strands are composed of several skills making up the strand's 'fibers.'
For language comprehension, students need knowledge, vocabulary, sentence structure, reasoning and a mental model. For word recognition, they need to know sounds, letters and words.
As those skills become more strategic and automatic, students develop a strong 'rope' of reading comprehension that they'll use to learn for the rest of their lives.
St. Hilaire says the body of research isn't an educational fad.
'This is how our kids need to learn how to read,' she said. 'To hear kids' excitement about reading, to hear teachers excited to be teaching reading — this is how reading needs to be taught.'
School board president Gabe Galbraith says he's heard students at all levels were staying engaged and are demonstrating strong understanding of the content.
'In addition to improving reading comprehension, it fosters critical thinking and problem-solving. Initial results are showing positive growth in our students testing,' Galbraith said in a statement.
'The process has been very collaborative with staff doing a tremendous job with the initial discussions and piloting material in classrooms. The community provided very positive review feedback and the board has spent significant time collecting feedback and observing lessons in classrooms,' he continued.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Business Wire

time4 days ago

  • Business Wire

Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

BOSTON--(BUSINESS WIRE)-- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update. 'Delivering on navenibart's best-in-class potential is our top priority, and enrollment in the global Phase 3 ALPHA-ORBIT trial is well underway with active sites across the U.S., U.K., Canada, Hong Kong, and South Africa' said Jill C. Milne, Ph.D., Chief Executive Officer at Astria Therapeutics. "We are encouraged by the strong enthusiasm from patients and physicians, including at the recent HAEA conference, where we had the opportunity to engage with the HAE community. We were also thrilled to announce a strategic partnership with Kaken. Their expertise supports our ongoing Phase 3 enrollment, contributes to strengthening our financial position, and may ultimately help expand global patient access to navenibart.' Navenibart (STAR-0215) In August, Astria announced that it has exclusively licensed development and commercialization rights in Japan to Kaken Pharmaceutical for navenibart. Under the agreement, Astria will receive an upfront payment of $16 million, with the potential for an additional $16 million in total commercialization and sales milestones. In addition to these payments, Astria is also eligible for tiered royalties with the royalty rate as a percentage of net sales up to 30%, and partial Phase 3 cost reimbursement. The navenibart Phase 3 program consists of the ALPHA-ORBIT Phase 3 trial and the ORBIT-EXPANSE long-term trial, which are designed to support registration globally. ALPHA-ORBIT is a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of navenibart over a 6-month treatment period, with dosing arms every 3 months (Q3M) and every 6 months (Q6M). Enrollment is ongoing and top-line results are expected in early 2027. After completing ALPHA-ORBIT, eligible patients may continue into the open-label ORBIT-EXPANSE study, which includes 6 months of additional treatment followed by a patient-centric flexible dosing phase. Positive initial results from the ongoing ALPHA-SOLAR long-term open-label trial of navenibart were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress. All 16 ALPHA-STAR target enrollment participants continued into ALPHA-SOLAR and the results are highly consistent with ALPHA-STAR - showing robust overall reduction in monthly attack rates (92% mean and 97% median) and a well-tolerated safety profile. STAR-0310 Astria is developing STAR-0310, an investigational high-potency and long-acting monoclonal antibody OX40 antagonist that incorporates YTE technology, for the treatment of atopic dermatitis (AD) and potentially other indications. STAR-0310 was intentionally designed to capitalize on the learnings of OX40 receptor and OX40 ligand programs with the goal of having the best overall OX40 therapy. The Company initiated a Phase 1a clinical trial of STAR-0310 in healthy subjects in January 2025. The Phase 1a trial is intended to assess the safety, tolerability, pharmacokinetics, and immunogenicity of STAR-0310 in healthy adult participants, with early proof-of-concept (POC) results expected in the third quarter of 2025. Data presented at the European Academy of Allergy and Clinical Immunology (EAACI) annual congress support STAR-0310 as a potential best-in-class OX40 antagonist, with a unique allosteric inhibition mechanism, enhanced disruption of OX40/OX40L signaling compared to other agents, and pure antagonistic activity without agonism. These findings, along with previously reported low ADCC activity and robust cytokine suppression, highlight STAR-0310's differentiated profile and its potential to achieve deeper inhibition of T cell responses. Upcoming Corporate Events Cantor Global Healthcare Conference (September 3-5, 2025, New York, New York) Second Quarter 2025 Financial Results Cash Position: As of June 30, 2025, Astria had cash, cash equivalents and short-term investments of $259.2 million, compared to $328.1 million as of December 31, 2024. The Company expects that its cash, cash equivalents and short-term investments as of June 30, 2025, together with the Kaken upfront payment and expected reimbursement of a portion of the Company's Phase 3 program costs, will be sufficient to fund its current operating plan into 2028, including (i) for navenibart, support for all program activities through completion of our ALPHA-ORBIT Phase 3 trial, including activities related to the planned ORBIT-EXPANSE long-term trial and Phase 3 development and testing of drug device combinations, and (ii) for STAR-0310, the completion of the ongoing Phase 1a clinical trial of healthy subjects. Net cash used in operating activities for the three months ended June 30, 2025 was $36.1 million, compared to $16.8 million for the three months ended June 30, 2024. R&D Expenses: Research and development expenses were $25.9 million for the three months ended June 30, 2025, compared to $20.7 million for the three months ended June 30, 2024. The increase in research and development expenses was attributed to an increase in navenibart expenses related to the support of the ALPHA-ORBIT clinical trial and employee expenses, partially due to increases in stock-based compensation and company growth to support the advancement of our programs, during the three months ended June 30, 2025. G&A Expenses: General and administrative expenses were $9.9 million for the three months ended June 30, 2025, compared to $8.1 million for the three months ended June 30, 2024. The increase in general and administrative expenses was attributable to company growth to support the advancement of our programs, stock-based compensation and other professional services. Operating Loss: Loss from operations was $35.8 million for the three months ended June 30, 2025, compared to $28.8 million for the three months ended June 30, 2024. Net Loss: Net loss was $33.1 million for the three months ended June 30, 2025, compared to a net loss of $24.2 million for the three months ended June 30, 2024. Net Loss Per Share Basic and Diluted: Net loss per share basic and diluted was $0.57 for the three months ended June 30, 2025, compared to a net loss basic and diluted of $0.43 per share for the three months ended June 30, 2024. About Astria Therapeutics: Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is an investigational monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is an investigational monoclonal antibody OX40 antagonist in clinical development for the treatment of atopic dermatitis. Learn more about our company on our website, or follow us on Instagram @AstriaTx and on Facebook and LinkedIn. Forward Looking Statements: This press release contains forward-looking statements within the meaning of applicable securities laws and regulations including, but not limited to, statements regarding: the expected timing of receipt of topline results from the navenibart ALPHA-ORBIT Phase 3 trial; the goals and objectives of the ALPHA-ORBIT Phase 3 trial and the ORBIT-EXPANSE long-term trial, including that they are designed to support registration of Q3M and Q6M navenibart administration; our goal of developing two dosing options for navenibart; the potential for navenibart in the HAE market, including the potential to be the market leading treatment in HAE, the potential therapeutic and other benefits of navenibart as a treatment for HAE, and our vision and goals for the program; the objectives, goals and potential payments from our agreement with Kaken Pharmaceutical; the potential therapeutic benefits and potential attributes of STAR-0310 as a treatment for AD; expectations regarding the nature and timing of receipt of early proof-of-concept results from such trial, including our expectation that such results will inform on STAR-0310's differentiated profile; the potential to develop STAR-0310 in additional indications; our goals and vision for STAR-0310; statements about the Company's current operating plan and the Company's anticipated cash runway; and the goal of bringing life changing therapies to patients and families affected by allergic and immunological diseases and to become a leading allergy and immunology company. The use of words such as, but not limited to, 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'goals,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would,' or "vision," and similar words expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Astria's current beliefs, expectations and assumptions regarding the future of its business, future plans and strategies, future financial performance, results of pre-clinical and clinical results of Astria's product candidates and other future conditions. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the following risks and uncertainties: changes in applicable laws or regulations; the possibility that we may be adversely affected by other economic, business, and/or competitive factors; risks inherent in pharmaceutical research and development, such as: adverse results in our drug discovery, preclinical and clinical development activities, the risk that the results of preclinical studies, including of navenibart and STAR-0310, may not be replicated in clinical trials, that the preliminary or interim results from clinical trials may not be indicative of the final results, that the results of early stage clinical trials, such as the results from the navenibart Phase 1a clinical trial and the initial results from the ALPHA-STAR trial, may not be replicated in later stage clinical trials, including additional and final results from the ALPHA-STAR trial or the planned navenibart Phase 3 development program; the risk that we may not be able to enroll sufficient patients in our clinical trials on a timely basis, and the risk that any of our clinical trials may not commence, continue or be completed on time, or at all; decisions made by, and feedback received from, the FDA and other regulatory authorities on our regulatory and clinical trial submissions and other feedback from potential clinical trial sites, including investigational review boards at such sites, and other review bodies with respect to navenibart, STAR-0310, and any other future development candidates, and devices for such product candidates; our ability to manufacture sufficient quantities of drug substance and drug product for navenibart, STAR-0310, and any other future product candidates, and devices for such product candidates, on a cost-effective and timely basis, and to develop dosages and formulation for navenibart, STAR-0310, and any other future product candidates that are patient-friendly and competitive; our ability to develop biomarker and other assays, along with the testing protocols therefore; our ability to obtain, maintain and enforce intellectual property rights for navenibart, STAR-0310, and any other future product candidates; our potential dependence on collaboration partners; competition with respect to navenibart, STAR-0310, or any of our other future product candidates; the risk that survey results and market research may not be accurate predictors of the commercial landscape for HAE, the ability of navenibart to compete in HAE and the anticipated position and attributes of navenibart in HAE based on clinical data to date, its preclinical profile, pharmacokinetic modeling, market research and other data; risks with respect to the ability of STAR-0310 to compete in AD and the anticipated position and attributes of STAR-0310 in AD based on its preclinical profile; our ability to manage our cash usage and the possibility of unexpected cash expenditures; our ability to obtain necessary financing to conduct our planned activities, including the costs associated with commercialization of navenibart if regulatory approval is obtained, and to manage unplanned cash requirements; the risks and uncertainties related to our ability to recognize the benefits of any additional acquisitions, licenses or similar transactions; and general economic and market conditions; as well as the risks and uncertainties discussed in the 'Risk Factors' sections of our Annual Report on Form 10-K for the period ended December 31, 2024 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, and in other filings that we may make with the Securities and Exchange Commission. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Astria may not actually achieve the forecasts or expectations disclosed in our forward-looking statements, and investors and potential investors should not place undue reliance on Astria's forward-looking statements. Neither Astria, nor its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing Astria's views as of any date subsequent to the date hereof. Astria Therapeutics, Inc. C onsolidated Statements of Operations (In thousands, except share and per share data) (Unaudited) Astria Therapeutics, Inc. Selected Consolidated Balance Sheets Data (In thousands) (Unaudited) June 30, December 31, 2025 2024 Assets Cash and cash equivalents $ 76,319 $ 59,820 Short-term investments 182,859 268,312 Right-of-use asset 4,546 5,114 Other current and long-term assets 18,200 9,117 Total assets 281,924 342,363 Liabilities and stockholders' equity Current portion of operating lease liabilities 1,399 1,384 Long term portion of operating lease liabilities 3,367 3,969 Other current and long-term liabilities 16,645 17,747 Total liabilities 21,411 23,100 Total stockholders' equity $ 260,513 $ 319,263 Expand Astria Therapeutics, Inc. Selected Consolidated Statements of Cash Flows Data (In thousands) (Unaudited) Six Months Ended June 30, 2025 2024 Net cash used in operating activities $ (70,076 ) $ (35,885 ) Net cash provided by (used in) investing activities 86,575 (194,334 ) Net cash provided by financing activities - 141,901 Net increase (decrease) in cash, cash equivalents and restricted cash $ 16,499 $ (88,318 ) Expand

Proposed spacecraft could carry up to 2,400 people on a one-way trip to the nearest star system, Alpha Centauri
Proposed spacecraft could carry up to 2,400 people on a one-way trip to the nearest star system, Alpha Centauri

Yahoo

time09-08-2025

  • Yahoo

Proposed spacecraft could carry up to 2,400 people on a one-way trip to the nearest star system, Alpha Centauri

When you buy through links on our articles, Future and its syndication partners may earn a commission. Engineers have designed a spacecraft that could take up to 2,400 people on a one-way trip to Alpha Centauri, the star system closest to our own. The craft, called Chrysalis, could make the 25 trillion mile (40 trillion kilometer) journey in around 400 years, the engineers say in their project brief, meaning many of its potential passengers would only know life on the craft. Chrysalis is designed to house several generations of people until it enters the star system, where it could shuttle them to the surface of the planet Proxima Centuri b — an Earth-size exoplanet that is thought to be potentially habitable. The project won first place in the Project Hyperion Design Competition, a challenge that requires teams to design hypothetical multigenerational ships for interstellar travel. Life on the Chrysalis Before boarding the ship, the Chrysalis project would require initial generations of ship inhabitants to live in and adapt to an isolated environment in Antarctica for 70 to 80 years to ensure psychological wellbeing. The ship could theoretically be constructed in 20 to 25 years and retains gravity through constant rotation. The vessel, which would measure 36 miles (58 km) in length, would be constructed like a Russian nesting doll, with several layers encompassing each other around a central core. The layers include communal spaces, farms, gardens, homes, warehouses and other shared facilities, each powered by nuclear fusion reactors. The core in the center of the vehicle hosts the shuttles that could bring people to Proxima Centuri b, as well as all of Chrysalis' communication equipment. Related: Will we ever reach Alpha Centauri, our closest neighboring star system? The layer closest to Chrysalis' core is dedicated to food production, nurturing plants, fungi, microbes, insects and livestock in controlled environments. To preserve biodiversity, different environments including tropical and boreal forests would be maintained. The second level from the center provides communal spaces, like parks, schools, hospitals and libraries, for the ship's inhabitants. The next shell would then hold dwellings for individual households, equipped with air circulation and heat exchangers. Work happens on the next level up, where there are facilities for industries ranging from recycling to pharmaceuticals to structural manufacturing. The fifth and outermost shell would serve as a warehouse for varied types of resources, materials, equipment and machinery. The Chrysalis' designers suggest that robots could run this level, reducing the need for human physical labor. Births would be planned in Chrysalis to ensure the population stays at a sustainable level, which the research team determined to be about 1,500 people — 900 people less than the ship's total capacity. Those responsible for the ship's governance would collaborate with artificial intelligence, "allowing for resilience of the whole social system, better knowledge transfer between the different generations of inhabitants and a deeper vision of the overall dynamics of the Chrysalis spaceship complex," the project engineers wrote in their pitch. RELATED STORIES —ChatGPT could pilot a spacecraft shockingly well, early tests find —China wants to build a mega spaceship that's nearly a mile long —Here's every spaceship that's ever carried an astronaut into orbit This plan is purely hypothetical, as some of the required technology, like commercial nuclear fusion reactors, don't yet exist. However, hypothetical projects like this one can still add to our existing knowledge base and help engineers improve upcoming designs. The Project Hyperion jury wrote on its website that Chrysalis was impressive for its "system-level coherence and innovative design of the modular habitat structure" and "overall depth of detail." The winning team of five researchers was awarded $5,000 USD. Human spaceflight quiz: How well do you know our journey into space?

Proposed spacecraft could carry up to 2,400 people on a one-way trip to the nearest star system, Alpha Centauri
Proposed spacecraft could carry up to 2,400 people on a one-way trip to the nearest star system, Alpha Centauri

Yahoo

time08-08-2025

  • Yahoo

Proposed spacecraft could carry up to 2,400 people on a one-way trip to the nearest star system, Alpha Centauri

When you buy through links on our articles, Future and its syndication partners may earn a commission. Engineers have designed a spacecraft that could take up to 2,400 people on a one-way trip to Alpha Centauri, the star system closest to our own. The craft, called Chrysalis, could make the 25 trillion mile (40 trillion kilometer) journey in around 400 years, the engineers say in their project brief, meaning many of its potential passengers would only know life on the craft. Chrysalis is designed to house several generations of people until it enters the star system, where it could shuttle them to the surface of the planet Proxima Centuri b — an Earth-size exoplanet that is thought to be potentially habitable. The project won first place in the Project Hyperion Design Competition, a challenge that requires teams to design hypothetical multigenerational ships for interstellar travel. Life on the Chrysalis Before boarding the ship, the Chrysalis project would require initial generations of ship inhabitants to live in and adapt to an isolated environment in Antarctica for 70 to 80 years to ensure psychological wellbeing. The ship could theoretically be constructed in 20 to 25 years and retains gravity through constant rotation. The vessel, which would measure 36 miles (58 km) in length, would be constructed like a Russian nesting doll, with several layers encompassing each other around a central core. The layers include communal spaces, farms, gardens, homes, warehouses and other shared facilities, each powered by nuclear fusion reactors. The core in the center of the vehicle hosts the shuttles that could bring people to Proxima Centuri b, as well as all of Chrysalis' communication equipment. Related: Will we ever reach Alpha Centauri, our closest neighboring star system? The layer closest to Chrysalis' core is dedicated to food production, nurturing plants, fungi, microbes, insects and livestock in controlled environments. To preserve biodiversity, different environments including tropical and boreal forests would be maintained. The second level from the center provides communal spaces, like parks, schools, hospitals and libraries, for the ship's inhabitants. The next shell would then hold dwellings for individual households, equipped with air circulation and heat exchangers. Work happens on the next level up, where there are facilities for industries ranging from recycling to pharmaceuticals to structural manufacturing. The fifth and outermost shell would serve as a warehouse for varied types of resources, materials, equipment and machinery. The Chrysalis' designers suggest that robots could run this level, reducing the need for human physical labor. Births would be planned in Chrysalis to ensure the population stays at a sustainable level, which the research team determined to be about 1,500 people — 900 people less than the ship's total capacity. Those responsible for the ship's governance would collaborate with artificial intelligence, "allowing for resilience of the whole social system, better knowledge transfer between the different generations of inhabitants and a deeper vision of the overall dynamics of the Chrysalis spaceship complex," the project engineers wrote in their pitch. RELATED STORIES —ChatGPT could pilot a spacecraft shockingly well, early tests find —China wants to build a mega spaceship that's nearly a mile long —Here's every spaceship that's ever carried an astronaut into orbit This plan is purely hypothetical, as some of the required technology, like commercial nuclear fusion reactors, don't yet exist. However, hypothetical projects like this one can still add to our existing knowledge base and help engineers improve upcoming designs. The Project Hyperion jury wrote on its website that Chrysalis was impressive for its "system-level coherence and innovative design of the modular habitat structure" and "overall depth of detail." The winning team of five researchers was awarded $5,000 USD. Human spaceflight quiz: How well do you know our journey into space?

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store